Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

Add videos to your saved list and come back to them any time.

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental A trio of respiratory illnesses — flu, COVID-19 and RSV — is sweeping the U.S. and leaving a trail of coughing and aching ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both companies ...